Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
The classification of Dry Eye Drugs includes Artificial Tears, Anti-inflammatory drugs and other, and the proportion of Artificial Tears in 2017 is about 89%.
North America is the largest consumption place, with a consumption market share nearly 40% in 2017. Following North America, Asia Pacific is the second largest consumption place with the consumption market share of 25%.

According to this study, over the next five years the Dry Eye Drugs market will register a 11.8% CAGR in terms of revenue, the global market size will reach US$ 9330 million by 2024, from US$ 5350 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Dry Eye Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Dry Eye Drugs market by product type, application, key manufacturers and key regions and countries.

This study considers the Dry Eye Drugs value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Artificial Tears
Anti-inflammatory Drugs
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Drug Stores
Online Pharmacies

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Allergan
Novartis AG
Valeant Pharmaceuticals
Santen Pharma
Shire
Johnson & Johnson
United Laboratories
Senju Pharmaceutical
Jianfeng Group
Eusan GMBH

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Dry Eye Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Dry Eye Drugs market by identifying its various subsegments.
Focuses on the key global Dry Eye Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Dry Eye Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Dry Eye Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.